Last reviewed · How we verify
ABSK-011
At a glance
| Generic name | ABSK-011 |
|---|---|
| Sponsor | Abbisko Therapeutics Co, Ltd |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Prospective Study to Evaluate the Safety and Efficacy of the Combination Therapy of Irpagratinib, Atezolizumab, and Bevacizumab in Patients With Hepatocellular Carcinoma (PHASE2)
- A Phase 2, Open-Label Study of ABSK-011 Combined Atezolizumab or SOC in HCC Patients (PHASE2)
- ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression (PHASE2)
- A Clinical Trial to Evaluate the Relative Bioavailability of New and Old ABSK-011 Capsules (PHASE1)
- A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-011 in Patients With Advanced Solid Tumor (PHASE1)
- FGF19 Overexpression Combination Unified Study in HCC-19 (PHASE2)
- A Mass Balance Study of [14C]ABSK011 (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ABSK-011 CI brief — competitive landscape report
- ABSK-011 updates RSS · CI watch RSS
- Abbisko Therapeutics Co, Ltd portfolio CI